Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
722 Views
Dr KK Aggarwal 19 October 2019
(Excerpts from NIH, Oct. 16, 2019): A multicenter randomized clinical trial evaluating a new artificial pancreas system has found that the new system was more effective than existing treatments at controlling blood glucose levels in people with type 1 diabetes. The research is published in the New England Journal of Medicine.
The NIH-funded study of people with type 1 diabetes showed that the system improved participants’ blood glucose control throughout the day and overnight.
The International Diabetes Closed-Loop (iDCL) Study involves five separate artificial pancreas clinical protocols implemented by 10 research centers in the United States and Europe.
The iDCL protocol enrolled 168 participants age 14 or older. They were randomly assigned to use either the artificial pancreas system (Control-IQ) or sensor-augmented pump (SAP) therapy with a continuous glucose monitor (CGM) and insulin pump that did not automatically adjust insulin throughout the day. Participants had contact with study staff every two to four weeks to download and review device data. No remote monitoring of the systems was done, so that the study would reflect real-world use.
Dr KK Aggarwal
Padma Shri Awardee
President Confederation of Medical Associations in Asia and Oceania (CMAAO)
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Past National President IMA
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}